VJHemOnc is committed to improving our service to you

ASCO 2019 | CITADEL-101 study- Parsaclisib in R/R B-cell malignancies

VJHemOnc is committed to improving our service to you

Tycel Phillips

Tycel Phillips, MD, of the University of Michigan, Ann Arbor, MI, discusses the CITADEL-101 trial (NCT02018861) investigating the maximum tolerated dose or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with itacitinib, This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter